Stephen J. Schuster

机构：Hospital of the University of Pennsylvania, Parker Institute for Cancer Immunotherapy, UPMC Hillman Cancer Center, University of Pennsylvania · ORCID：0000-0002-3376-8978

发表论文 829 篇 · 总被引 34521 次 · h-index 78

代表论文

• Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma (2025 · Journal of Clinical Oncology · 被引 16)
• β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer (2026 · Cell · 被引 14)
• Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study (2026 · The Lancet · 被引 10)
• Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma (2026 · Blood Advances · 被引 5)
• Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis (2026 · American Journal of Hematology · 被引 4)
• Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation (2026 · Blood Advances · 被引 3)